IGF-1 Signaling Cascade

What IGF-1 signaling does

Insulin-like growth factor 1 (IGF-1) carries out much of growth hormone's effect on tissue growth. The liver makes most of the IGF-1 in blood, while muscle makes its own for local use; how the two sources split the work is still debated (Yoshida and Delafontaine, 2020). Neighboring pathways are covered in our overview of cellular signaling.

From receptor to protein synthesis

The IGF-1 receptor (IGF-1R) is a tyrosine kinase. Once IGF-1 binds, the receptor phosphorylates an adaptor called IRS-1, which recruits PI3K. PI3K makes the membrane lipid PIP3. Akt docks there and is switched on, which is why this stretch is called the PI3K/Akt pathway (Schiaffino and Mammucari, 2011).

Akt pushes the muscle protein balance from both ends. It raises synthesis through mTORC1 and by switching off GSK3β. It also slows breakdown by blocking FOXO, which drives two muscle-specific ubiquitin ligases (Yoshida and Delafontaine, 2020). mTORC1 answers to amino acids and to AMPK, the cell's energy sensor, as well as to IGF-1; see our pages on the mTOR pathway and AMPK activation.

IGF-1R also signals through the Ras-ERK (MAPK) branch, which cell-culture work tied mainly to proliferation. Yet in a 14-day rat study, blocking that branch also stopped IGF-1's gain in muscle protein (Haddad and Adams, 2004).

Most of this map comes from cells and genetically modified rodents. Mice with a blocked IGF-1 receptor in muscle still grew normally after surgical overload, so IGF-1's role in load-driven growth of adult muscle is unsettled (Schiaffino and Mammucari, 2011).

Binding proteins set the timing

About 98% of IGF-1 in blood is bound to one of six IGF binding proteins (IGFBPs), mostly IGFBP-3. Binding decides how long it lasts. Free IGF-1 has a half-life under 10 minutes, while IGF-1 held in the large ternary complex with IGFBP-3 lasts more than 16 hours (Yoshida and Delafontaine, 2020). IGFBPs also keep IGF-1 away from the insulin receptor, which it binds weakly. Free IGF-1 reaching that receptor can cause hypoglycemia.

How peptides feed the cascade

Growth hormone secretagogues and GHRH analogs act upstream. They raise growth hormone, and the liver answers with more IGF-1. In healthy adults, a single injection of CJC-1295 raised mean IGF-1 1.5- to 3-fold for 9-11 days (Teichman et al., 2006). In a two-year trial in 65 adults aged 60-81, MK-677 brought IGF-1 up to young-adult levels. Fat-free mass rose about 1.1 kg. Strength and function didn't change, and insulin sensitivity fell (Nass et al., 2008).

Direct analogs and the IGF-1 LR3 half-life

IGF-1 LR3 skips those steps and binds IGF-1R directly. It is human IGF-1 with arginine at position 3 plus a 13-amino-acid extension. Those changes cut its affinity for IGFBPs about 1,000-fold. In 14-day rat studies, LR3 was about 6 times more potent than IGF-1 for growth (Ballard et al., 1993).

Vendor pages and forum guides often give LR3 a half-life of 20-30 hours. The evidence doesn't support that:

• No human data. As of October 2026, no published study has measured LR3 levels in people, and a ClinicalTrials.gov search we ran that month found no registered trials.
• Rats clear it faster. In a 1993 IV study, LR3 left rat plasma at 9.84 ml/min per kg against 0.90 for IGF-1, about 11 times faster. Most LR3 circulated free, while most IGF-1 sat in the ternary complex (Bastian et al., 1993). That is what the binding-protein picture predicts.
• No measured source. An independent evidence ledger traced the 20-30 hour figure to an uncited methods line in a 2011 mouse study that didn't measure half-life (Vialog, 2026). We couldn't open that paper's full text to confirm the wording.

Fast clearance doesn't mean a short effect. In pigs, variants that bind IGFBPs poorly (LR3 among them) lowered blood glucose more than IGF-1 did, and for longer. Total lowering over four hours was about 4-8 times greater (Tomas et al., 1997). Hypoglycemia is also the acute risk users mention most. With only animal data on either question, the evidence for LR3 is preliminary. Our IGF-1 LR3 profile covers what users report.

Des(1-3) IGF-1 is a truncated form that barely binds IGFBPs; in rats it cleared about four times faster than IGF-1 (Ballard et al., 1991). MGF usually means a splice variant of IGF-1 that rises in exercised muscle, though some studies use the name for its E-peptide tail alone. In cell culture that tail acted without the IGF-1 receptor (Yoshida and Delafontaine, 2020), so synthetic MGF may sit outside this cascade.

What we still don't know

Without human pharmacokinetic data, any LR3 schedule built on a half-life figure is guesswork. It's also unclear whether raising IGF-1 helps healthy adults, since the best long-term human data show more lean mass without more strength.